B

BioMarin Pharmaceutical
D

BMRN

62.400
USD
-0.09
(-0.14%)
Market Open
Volume
5,081
EPS
4
Div Yield
-
P/E
38
Market Cap
11,901,909,349
OverviewSignalsIdeasNews
Related Instruments
    AMGN
    AMGN
    -0.58
    (-0.21%)
    273.95 USD
    BIIB
    BIIB
    1.630
    (1.16%)
    142.570 USD
    GILD
    GILD
    -0.430
    (-0.46%)
    92.520 USD
    I
    INCY
    -0.810
    (-1.10%)
    72.660 USD
    REGN
    REGN
    10.97
    (1.60%)
    698.29 USD
    VRTX
    VRTX
    3.85
    (0.90%)
    431.47 USD
    More
News

Title: BioMarin Pharmaceutical

Sector: Healthcare
Industry: Biotechnology
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Trading. Social. Simple.
FacebookTwitterYoutube
Company
Contact usAbout usTerms Of UsePrivacy PolicyCookies PolicyDisclaimerHelp Center
Social Network
The NetworkSignals NetworkIdeas NetworkBest Traders
Products
Risk CalculatorPip CalculatorAdvance Chart
Markets
Exchange RatesCommodities RatesCryptocurrencies RatesIndices RatesUS Stocks Rates
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.